

UTILITY
PATENT APPLICATION
TRANSMITTAL

Attorney Docket No. AFD 489

First Inventor or Application Identifier Harvey A. Schwertner

Title COMBINED CHOLESTEROL AND BILIRUBIN TESTS AS RISK
PREDICTORS FOR CORONARY ARTERY DISEASE

Express Mail Label No.

APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)

2. ☐ Applicant claims small entity status
(See 37 CFR 1.27)

3. ☒ Specification [Total Pages 22]
(Preferred arrangement set forth below)
- Descriptive title of the invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference to sequence listing, a table, or a
computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 6]

5. ☐ Oath or Declaration [Total Pages 2]
a. ☐ Newly executed (original or copy)
b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).

6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
a. ☐ Computer Readable Form (CRF)
b. Specification Sequence Listing on:
i. ☐ CD-ROM or CD-R (2 copies); or
ii. ☐ Paper
c. ☐ Statements verifying identity of above copies

9. ☐ Assignment Papers (cover sheet & document(s))

10. ☐ 37 CFR 1.373(b) Statement ☐ Power of Attorney

11. ☐ English Translation Document (if applicable)

12. ☐ Information Disclosure Statement (IDS) PTO-1449 ☐ Copies of IDS Citations

13. ☐ Preliminary Amendment

14. ☒ Return Receipt Postcard (MPEP 503) (should be itemized)


15. ☐ Certified Copy of Priority Document(s)

16. ☒ Request and Certification under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach for PTO/SB/35 or its
equivalent.

17. ☒ Other: Certificate of 37 CFR 1.10 Express Mailing

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an
Application Data Sheet under 37 CFR 1.76
☐ Continuation ☐ Divisional ☐ Continuation in Part (CIP) of prior application No: _____
Prior application information: Examiner _____ Group / Art Unit _____
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied
under Box 5B, is considered to be a part of the disclosure of the accompanying continuation or divisional application and is hereby
incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted
application parts.

CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label  or ☐ Correspondence address below
(Insert Customer No. or attach bar code label here)

Name FREDRIC L. SINDER 26902

Address AFMC LO/JAZ
BLDG 11, ROOM 100 PATENT TRADEMARK OFFICE
2240 B STREET

City WRIGHT-PATTERSON AFB State OH Zip Code 45433-7109

Country U.S.A. Telephone (937) 255-2838 Fax (937) 255-3733

Name (Print / Type) FREDRIC L. SINDER Registration No. (Attorney / Agent) 28,475

Signature [Signature] Date 9 Nov 01

FEE TRANSFERTAL for FY 2002

Patent fees are subject to annual revision.

Complete if Known

Application Number

Filing Dat

First Named Inventor

Harvey A. Schwertner

Examiner Name

Group Art Unit

Attorney Docket Number

AFD 489

TOTAL AMOUNT OF PAYMENT

(\$ 740.00

METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account
Number

AF 01-0465

Deposit Account
Name

Department of the Air Force

- ☒ Charge Any Additional Fee Required under 37 CFR 1.16 and 1.17 ☐ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit Card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Lge Entity Fee Code	Lge Entity Fee (\$)	Sm. Entity Fee Code	Sm. Entity Fee (\$)	Fee Description	Fee Paid
001	740	201	370	Utility Filing Fee	740
006	330	206	165	Design Filing Fee	
107	510	207	255	Plant Filing Fee	
108	740	208	370	Reissue Filing Fee	
114	160	214	80	Provisional Filing Fee	

SUBTOTAL (1) (\$ 740.00

2. EXTRA CLAIM FEES

Total Claims	Extra	Fee from below	Fee Paid
- 20** =	0	18	0
Independent claims - 3 =	0	84	0
Multiple dependent claims			

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee code	Fee (\$)	
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim
109	84	209	42	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) \$

** or number previously paid, if greater; For Reissues, see below

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Code	Large Entity Fee (\$)	Small Entity Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner Action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1440	218	720	Extension for reply within fourth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times # of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR §1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR §1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	


Other fee (specify) _____

SUBTOTAL (3) \$ 0

*Reduced by Basic Filing Fee Paid

SUBMITTED BY

Complete (if applicable)

Typed or Printed Name	FREDRIC L. SINDER	Registration. No.	28,475	Telephone	(937) 255-2838
Signature		Date	9 Nov 01		
Typed or Printed Name		Registration. No.		Telephone	
Signature		Date			

**REQUEST AND CERTIFICATION
UNDER
35 U.S.C. 122(b)(2)(B)(i)**

First Named Inventor Harvey A. Schwertner
Title COMBINED CHOLESTEROL AND BILIRUBIN
TESTS AS RISK PREDICTORS FOR
CORONARY ARTERY DISEASE
Atty Docket Number AFD 489

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 1.22(b).

9 Mar 01
Date


Signature

FREDRIC L. SINDER
Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and be submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 US.C. 122(b)(2)(B)(iii)).**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Harvey A. Schwertner et al

Group Art Unit:

Serial No.: (AFD 489)

Examiner:

Filed:

For: COMBINED CHOLESTEROL AND BILIRUBIN TESTS AS
RISK PREDICTORS FOR CORONARY ARTERY DISEASE

**CERTIFICATE OF MAILING
BY "EXPRESS MAIL" UNDER 37 CFR 1.10**

"Express Mail" mailing label number EH 555040918 US

Date of Deposit: November 9, 2001

I certify that this patent application is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above from AFMC LO/JAZ, Bldg 11, Room 100, 2240 B Street, Wright-Patterson Air Force Base, Ohio 45433-7109 and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington DC 20231.



FREDRIC L. SINDER, Reg. No. 28,475
Attorney for Applicants

FL Sinder
937/255-2838